TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults) [version 1; peer review: 3 approved]

TRUE-1: Trial of Repurposed Unithiol for snakebite Envenoming phase 1 (safety, tolerability, pharmacokinetics and pharmacodynamics in healthy Kenyan adults) [version 1; peer review: 3 approved]

Background: Snakebites affect over 5 million people each year, and over 100,000 per year die as a result. The only available treatment is antivenom, which has many shortcomings including high cost, intravenous administration, and high risk of adverse events. One of the most abundant and harmful comp...

Full description

Bibliographic Details
Main Authors: Mainga Hamaluba, Debra Riako, Betty Kalama, Francis M. Ndungu, Hope Mwangudzah, Saye Khoo, David G. Lalloo, Lawrence Babu, Richard FitzGerald, Michael Abouyannis, Benedict Orindi, Samson Ngome, Mwanajuma Ngama, Yvonne K. Nyambura, Laura Else, Frida Lewa, Noni Mumba, Ifedayo Adetifa, Sujan Dily Penchala, Nicholas R. Casewell
Format: Article
Language:English
Published: Wellcome 2022-03-01
Series:Wellcome Open Research
Subjects:
Snakebite
envenoming
small molecule
chelator
phase I
adaptive
eng
Online Access:https://wellcomeopenresearch.org/articles/7-90/v1

Internet

https://wellcomeopenresearch.org/articles/7-90/v1

Similar Items